# A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

> **NCT03875079** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 83 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** RO6874281
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03875079
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-24
- **Primary completion:** 2022-07-14
- **Final completion:** 2022-07-14
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03875079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03875079, "A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03875079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*